# Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant

> **NCT00530218** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 61 (actual)

## Conditions studied

- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
- Leukemia
- Lymphoma
- Multiple Myeloma
- MDS
- Myelodysplastic/Myeloproliferative Diseases

## Interventions

- **DRUG:** Ganciclovir

## Key facts

- **NCT ID:** NCT00530218
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-03
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2017-12-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00530218

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00530218, "Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00530218. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*